In their questioning, the judges appeared sympathetic to anti-abortion medical group plaintiffs who claimed the FDA did not adequately consider alleged safety problems of mifepristone when it first approved the drug in 2000.
In their questioning, the judges appeared sympathetic to anti-abortion medical group plaintiffs who claimed the FDA did not adequately consider alleged safety problems of mifepristone when it first approved the drug in 2000.